GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $21.07 and traded as low as $21.03. GENMAB A/S/S shares last traded at $21.29, with a volume of 860,581 shares traded.
GENMAB A/S/S Stock Up 1.5 %
The firm’s 50 day moving average price is $21.07 and its two-hundred day moving average price is $23.94.
GENMAB A/S/S Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
See Also
- Five stocks we like better than GENMAB A/S/S
- How to Invest in the FAANG Stocks
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How to Use the MarketBeat Dividend Calculator
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
